Collaborations & Alliances

Bayer, BMS, Ono to Collaborate on Colorectal Cancer Treatments

Aims to evaluate the combination of Bayer's Stivarga and BMS / Ono's Opdivo in patients with MSS mCRC

Bayer, Bristol-Myers Squibb Co. and Ono Pharmaceutical Co., Ltd. have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga (regorafenib) and BMS / Ono’s anti-PD-1 immune checkpoint inhibitor, Opdivo (nivolumab) in patients with micro-satellite stable metastatic colorectal cancer (MSS mCRC), the most common form of mCRC.   Regorafenib as a monotherapy, has demonstrated an overall survival benefit versus placebo in the pivot...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters